| Nicole Jordan, MD | |
|
7600 River Rd, North Bergen, NJ 07047-6217 | |
| (201) 854-5005 | |
| Not Available |
| Full Name | Nicole Jordan |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 10 Years |
| Location | 7600 River Rd, North Bergen, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013304989 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MA10437000 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Barnabas Medical Center | Livingston, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rwjbh Emergency Medicine Associates, Llc | 0941612840 | 613 |
News Archive
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
A new comprehensive review, recently published in Critical Reviews in Food Science and Nutrition, concludes that fructose does not increase food intake or impact body weight or blood triglycerides in overweight or obese individuals.
Scientists at St. Jude Children's Research Hospital are advancing understanding of a potential Alzheimer's disease treatment.
Many cardiac implantable electronic device models currently in use were approved via a Food and Drug Administration review process in which the models were assumed safe and effective based on approval of prior versions of the device, according to a study in the January 22/29 issue of JAMA.
› Verified 2 days ago
| Entity Name | Excel Urgent Care Of Paramus Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063652220 PECOS PAC ID: 3971656018 Enrollment ID: O20090806000449 |
News Archive
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
A new comprehensive review, recently published in Critical Reviews in Food Science and Nutrition, concludes that fructose does not increase food intake or impact body weight or blood triglycerides in overweight or obese individuals.
Scientists at St. Jude Children's Research Hospital are advancing understanding of a potential Alzheimer's disease treatment.
Many cardiac implantable electronic device models currently in use were approved via a Food and Drug Administration review process in which the models were assumed safe and effective based on approval of prior versions of the device, according to a study in the January 22/29 issue of JAMA.
› Verified 2 days ago
| Entity Name | Doctors Office Of West Caldwell Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144524786 PECOS PAC ID: 7416130448 Enrollment ID: O20110329000053 |
News Archive
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
A new comprehensive review, recently published in Critical Reviews in Food Science and Nutrition, concludes that fructose does not increase food intake or impact body weight or blood triglycerides in overweight or obese individuals.
Scientists at St. Jude Children's Research Hospital are advancing understanding of a potential Alzheimer's disease treatment.
Many cardiac implantable electronic device models currently in use were approved via a Food and Drug Administration review process in which the models were assumed safe and effective based on approval of prior versions of the device, according to a study in the January 22/29 issue of JAMA.
› Verified 2 days ago
| Entity Name | North Bergen Hospitalists |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689028946 PECOS PAC ID: 6002107976 Enrollment ID: O20160623001331 |
News Archive
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
A new comprehensive review, recently published in Critical Reviews in Food Science and Nutrition, concludes that fructose does not increase food intake or impact body weight or blood triglycerides in overweight or obese individuals.
Scientists at St. Jude Children's Research Hospital are advancing understanding of a potential Alzheimer's disease treatment.
Many cardiac implantable electronic device models currently in use were approved via a Food and Drug Administration review process in which the models were assumed safe and effective based on approval of prior versions of the device, according to a study in the January 22/29 issue of JAMA.
› Verified 2 days ago
| Entity Name | Rwjbh Emergency Medicine Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912510041 PECOS PAC ID: 0941612840 Enrollment ID: O20201217002547 |
News Archive
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
A new comprehensive review, recently published in Critical Reviews in Food Science and Nutrition, concludes that fructose does not increase food intake or impact body weight or blood triglycerides in overweight or obese individuals.
Scientists at St. Jude Children's Research Hospital are advancing understanding of a potential Alzheimer's disease treatment.
Many cardiac implantable electronic device models currently in use were approved via a Food and Drug Administration review process in which the models were assumed safe and effective based on approval of prior versions of the device, according to a study in the January 22/29 issue of JAMA.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicole Jordan, MD Po Box 4126, Torrance, CA 90510-4126 Ph: () - | Nicole Jordan, MD 7600 River Rd, North Bergen, NJ 07047-6217 Ph: (201) 854-5005 |
News Archive
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
A new comprehensive review, recently published in Critical Reviews in Food Science and Nutrition, concludes that fructose does not increase food intake or impact body weight or blood triglycerides in overweight or obese individuals.
Scientists at St. Jude Children's Research Hospital are advancing understanding of a potential Alzheimer's disease treatment.
Many cardiac implantable electronic device models currently in use were approved via a Food and Drug Administration review process in which the models were assumed safe and effective based on approval of prior versions of the device, according to a study in the January 22/29 issue of JAMA.
› Verified 2 days ago
Evelyn Camacho-patterson, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 7800 Palisade Ave, North Bergen, NJ 07047 Phone: 201-868-0001 | |
Dr. Harold George Tepler, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9225 Kennedy Blvd, Suite D, North Bergen, NJ 07047 Phone: 201-868-2849 Fax: 201-868-4190 | |
Dr. Sanjay Lloyd Sookhu, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7600 River Rd, North Bergen, NJ 07047 Phone: 201-854-5713 | |
Luis Enrique Vazquez Falcon, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7225 Bergenline Ave, First Floor, North Bergen, NJ 07047 Phone: 201-758-8012 Fax: 201-758-8012 | |
Tanmay Pradip Gosalia, D.O., M.P.H., M.A. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9225 John F Kennedy Boulevard, Summit Medical Arts, North Bergen, NJ 07047 Phone: 201-453-2800 | |
Dr. Stuart Leigh Goldberg, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7650 River Rd, North Bergen, NJ 07047 Phone: 201-464-0008 Fax: 201-662-1267 |